Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
Talia Golan(Sheba Medical Center), Hedy L. Kindler(University of Chicago), Michael J. Hall(Fox Chase Cancer Center), Hana Algül(TUM Klinikum), David McGuinness(Université Paris Cité), Anke Reinacher‐Schick(Ruhr University Bochum), Karen Cui(Université Paris Cité), Katia Schlienger(United States Military Academy), Joon Oh Park(Samsung Medical Center), Giampaolo Tortora(University of Naples Federico II), Dirk Arnold(Asklepios Klinik Altona), Do‐Youn Oh(Seoul National University Hospital), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Teresa Macarulla(Vall d'Hebron Hospital Universitari), Daniel Hochhauser(Royal London Hospital), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Michele Reni(San Raffaele University of Rome), Pascal Hammel(Université Paris Cité), Gershon Y. Locker(AstraZeneca (United States))
Cited by 78
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k